About vasopharm
Corporate Profile
Mission
We develop novel therapeutics for acute inflammatory central nervous system conditions by targeting nitric oxide signalling pathways.
Business Model
vasopharm focuses on drug development in central nervous system (CNS) niche indications with a high unmet medical need. We have taken a small molecule (VAS203) targeting pathological nitric oxide (NO) production and signalling from discovery to a pivotal clinical trial.
History
vasopharm was founded in July 1998 as a spin-off from the University of Wuerzburg Medical School by Harald Schmidt, MD, PhD, Professor of Pharmacology and Toxicology, and Ulrich Walter, MD, Professor of Clinical Biochemistry and Pathobiochemistry. In December 2015, vasopharm closed a Series G financing round amounting to EUR 22 million followed by enrolling the first patient in to the NOSTRA III trial – a phase III clinical trial assessing efficacy and safety of VAS203 for the treatment of moderately to severely injured closed head traumatic brain injury patients in September 2016. The NOSTRA III trial was successfully completed in June 2020 with data lock in July 2020.
| 2021, Mar. | Successful completion of validation of drug substance manufacturing process |
| 2021, Jan. | Prof Stover, MD joins vasopharm as new Chief Medical Officer |
| 2020, Jun. | Last Patient Last Visit of NOSTRA III trial |
| 2019, Dec. | Last patient enrolled into NOSTRA III trial |
| 2019, Jan. | Efficacy Interim Analysis of NOSTRA III trial by DMC |
| 2018, Jul. | 3rd Safety Interim Analysis of NOSTRA III trial by DMC |
| 2017, Dec. | 2nd Safety Interim Analysis of NOSTRA III trial by DMC |
| 2017, Jul. | 1st Safety Interim Analysis of NOSTRA III trial by DMC |
| 2017, Feb | Successful completion of clinical phase Ic trial in healthy volunteers |
| 2016, Nov | Appointment of new Chief Medical Officer |
| 2016, Sep | First Patient In – NOSTRA III trial; a European placebo-controlled, randomised, double-blind, multi-centre study in patients with moderate and severe traumatic brain injury |
| 2015, Dec. | Series G Financing Round (EUR 22.0 m) |
| 2013, Jun | Series F Financing Round (EUR 5.0 m) |
| 2012, Apr | Completion of patient treatment in phase IIa NOSTRA trial with VAS203 |
| 2009, Nov | First Patient In phase IIa explorative European multicentre trial |
| 2009, May | Series D Financing round (EUR 4.5 m) |
| 2008, Jun | Successful completion of clinical phase Ib study with multiple application of vasopharm’s compound VAS203 |
| 2007, Jul | Successful completion of first-in-man study with vasopharm's compound VAS203 |
| 2006, Dec | First human study with vasopharm's trauma compound VAS203 |
| 2006, Sep | European Commission Grants Orphan Medicinal Product Designation for vasopharm's drug candidate VAS203 |
| 2006, Jan | Series B Financing round with EMBL Ventures as Lead Investor (EUR 9.7 m) |
| 2004, Nov | New investor Entrepreneurs Fund B.V., Amsterdam |
| 2004, Oct | Patent license agreement with Pfizer Inc., USA |
| 2004, Feb | Grant of the Bavarian Research Foundation for Nox inhibitors |
| 2003, Mar | Start of GMP production of VAS203 |
| 2002, Oct | License Agreement with BioCytex, Marseille (Cytometric VASP Assay for Clopidogrel® monitoring) |
| 2001, Aug | Series A Financing round with 3i Group Investments LP as Lead Investor (EUR 6.5 m) |
| 1998, Jul | Foundation of vasopharm; Business Model: Fee for Service for the pharmaceutical industry until end of 2000 |